Tech Company Inital Public Offerings
AbSci IPO
AbSci was purchased by . Shares started trading on 7/26/2021.
Transaction Overview
Company Name
Announced On
7/26/2021
Transaction Type
IPO
Amount
$200,000,000
Proceeds Purpose
We currently expect to use our net proceeds from this offering, together with our existing cash and cash equivalents, to further our investment in expanding our Integrated Drug Creation Platform's capabilities, continued growth of our business development organization and activities, and for general corporate purposes, including working capital, capital expenditures, and operating expenses. We may also use a portion of the remaining net proceeds, if any, to acquire complementary businesses, products, services or technologies, including scientific expertise, although we have no binding agreements or commitments to do so at this time.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
101 E 6th St. 350
Vancouver, WA 98660
USA
Vancouver, WA 98660
USA
Phone
Website
Email Address
Overview
AbSci is a global leader in cutting-edge protein production technologies committed to reducing costs in the biopharmaceutical industry.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Sean McClain
Chief Financial Officer
Gregory Schiffman
Chief Operating Officer
Andrew Pihl
Chief Technical Officer
Matthew Weinstock
VP - General Counsel
Lawrence McClure
Browse more venture capital transactions:
Prev: 7/26/2021: US Mobile venture capital transaction
Next: 7/26/2021: Paradromics venture capital transaction
Share this article
Where The Data Comes From
We report on tech company VC transactions. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs